Cellectis (NASDAQ:CLLS) Upgraded to “Buy” by BidaskClub

Cellectis (NASDAQ:CLLS) was upgraded by stock analysts at BidaskClub from a “hold” rating to a “buy” rating in a report issued on Thursday, BidAskClub reports.

CLLS has been the subject of several other reports. BTIG Research assumed coverage on shares of Cellectis in a report on Friday, August 9th. They set a “buy” rating and a $37.00 price target for the company. Zacks Investment Research raised shares of Cellectis from a “hold” rating to a “buy” rating and set a $15.00 target price for the company in a research note on Tuesday, November 12th. Finally, Goldman Sachs Group set a $20.00 target price on shares of Cellectis and gave the stock a “hold” rating in a research note on Monday, August 12th. Three analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Cellectis has a consensus rating of “Buy” and an average price target of $28.80.

Shares of CLLS stock opened at $14.58 on Thursday. Cellectis has a 12-month low of $9.50 and a 12-month high of $21.14. The company has a market capitalization of $590.05 million, a P/E ratio of -7.55 and a beta of 1.82. The firm has a 50-day moving average price of $12.48 and a 200 day moving average price of $13.56. The company has a quick ratio of 7.93, a current ratio of 7.99 and a debt-to-equity ratio of 0.12.

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Point72 Asset Management L.P. raised its stake in shares of Cellectis by 32.6% in the third quarter. Point72 Asset Management L.P. now owns 189,000 shares of the biotechnology company’s stock worth $1,966,000 after acquiring an additional 46,500 shares during the last quarter. Sumitomo Mitsui Trust Holdings Inc. raised its stake in shares of Cellectis by 8.6% in the third quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 1,314,295 shares of the biotechnology company’s stock worth $13,669,000 after acquiring an additional 104,276 shares during the last quarter. Nikko Asset Management Americas Inc. raised its stake in shares of Cellectis by 7.3% in the third quarter. Nikko Asset Management Americas Inc. now owns 1,314,295 shares of the biotechnology company’s stock worth $13,669,000 after acquiring an additional 89,961 shares during the last quarter. Envestnet Asset Management Inc. raised its stake in shares of Cellectis by 22.1% in the third quarter. Envestnet Asset Management Inc. now owns 50,228 shares of the biotechnology company’s stock worth $522,000 after acquiring an additional 9,088 shares during the last quarter. Finally, OneAscent Financial Services LLC bought a new position in shares of Cellectis in the second quarter worth about $257,000. 30.97% of the stock is owned by institutional investors.

Cellectis Company Profile

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia (ALL); UCART22 to treat ALL and non-Hodgkin lymphoma (NHL); ALLO-501 for treating relapsed/refractory NHL; and UCART123 for the treatment of acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm.

Featured Story: What is the Moving Average Convergence Divergence (MACD) oscillator?

Analyst Recommendations for Cellectis (NASDAQ:CLLS)

Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.